Phase I/II Advanced HER2+ Breast Cancer Study
Biotech with a promising compound but a highly complex protocol design and a scarcity of comparator arm naïve patients in the U.S.
A biotech with a promising compound but a highly complex protocol design was facing a scarcity of comparator arm naïve patients in the U.S. The trial had been ongoing for 6 months at 7 sites in the U.S.
See how Canada recruited 55% of the patients with only 33% of the sites.
Complete This Form
To Download